IO BIOTECH INC. - COMMON STOCK

IO Biotech Hosting Key Opinion Leader Webinar Series

22 Apr 2022 07:33:34 By Nasdaq GlobeNewswire

IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

12 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

08 Apr 2022 15:15:00 By Nasdaq GlobeNewswire

IO Biotech Announces Year-End Results for 2021

31 Mar 2022 15:15:00 By Nasdaq GlobeNewswire

IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022

08 Mar 2022 15:30:00 By Nasdaq GlobeNewswire

IO Biotech to Present at 42nd Annual Cowen Healthcare Conference

04 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Appointment of David V. Smith to its Board of Directors

03 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

09 Dec 2021 10:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

06 Dec 2021 07:00:04 By Nasdaq GlobeNewswire

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

09 Nov 2021 10:06:22 By Nasdaq GlobeNewswire